Novavax on Thursday tried to calm investors spooked by the delay of full approval of its COVID vaccine shot by U.S.

Novavax said on Thursday discussions with the U.S. health regulator on its COVID-19 shot are ongoing and a pathway to ...

Novavax is undervalued, presenting an attractive risk-reward profile for long-term investors. Click here to find out why NVAX ...

After more than a month of speculation over how the FDA will rule on Novavax’s application for an updated formulation of its ...

Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the first quarter ended ...

Novavax posts $667 million in Q1 2025 revenue and $2.93 EPS, boosted by Sanofi payments and APA terminations; full-year ...

Novavax Inc (NVAX) reports a dramatic revenue increase and strategic collaborations, while navigating regulatory hurdles and ...

Reports of severe adverse events in some people who received the chikungunya vaccine have spurred regulators in Europe and ...

Novavax sees pathway to FDA approval after post-marketing commitments Swings to profit in Q1 Shares rise nearly 19% May 8 (Reuters) - Novavax (NVAX.O), opens new tab on Thursday tried to calm ...

In the wake of mass restructuring efforts across the Department of Health and Human Services (HHS), the FDA has missed yet ...

An FDA committee will soon make recommendations about this fall’s Covid-19 vaccines while Novavax still awaits full FDA ...

First, to the best of your knowledge, is the post-marketing clinical trial requirement specific to Novavax's BLA filing or do you expect FDA will ask all COVID-19 vaccines, including the mRNA ...